Group 1 - The core viewpoint of the article emphasizes the promotion of high-quality development in the pharmaceutical retail industry through optimized marketing systems and collaboration between pharmaceutical manufacturers and large distribution companies [1] - The opinion encourages the sale of innovative drugs and reference preparations through retail pharmacies, aiming to enhance market competition across provinces and regions [1] - It advocates for the establishment of a reasonable pricing system for retail drugs, ensuring fair competition and monitoring price linkages between online and offline sales [1] Group 2 - The article highlights the importance of data sharing by encouraging e-commerce platforms to open data interfaces for better price monitoring and comparison [1] - It promotes the application of price comparison tools and indices for insured drugs in designated pharmacies to improve transparency and consumer access [1]

智通财经APP获悉，1月22日，商务部等9部门关于促进药品零售行业高质量发展的意见，支持零售药店 进行兼并重组。鼓励药品零售企业依法开展横向并购与重组。鼓励各地优化营商环境，对于被整合的连 锁或单体药店，优化《药品经营许可证》申请核发流程。涉及医保资质变更的，允许原医保资质继续存 续和使用，新医保资质正式开通后，注销原医保资质。 推动药品零售企业参加药品集中采购。鼓励行业协会或区域医药流通龙头企业牵头，引导药品零售企业 参与药品集中带量采购。针对其他药品，鼓励零售药店整合采购需求，开展联合采购，实现量价挂钩， 提升议价能力。支持药品零售企业按规定通过省级医药采购平台采购，生产企业需做好供应保障。 原文如下： 商务部等9部门关于促进药品零售行业高质量发展的意见 药品零售行业是国家医药卫生事业的重要组成部分，关系人民健康和生命安全。为贯彻落实党中央、国 务院有关决策部署，强化药品零售行业专业服务、健康促进、应急保供等功能，打造更好服务人民医药 健康需求的"健康驿站"，现提出如下意见： 一、总体要求 坚持以习近平新时代中国特色社会主义思想为指导，全面贯彻党的二十大和二十届历次全会精神，坚持 政府引导与市场主导相结合 ...

Core Viewpoint - The document outlines the opinions from the Ministry of Commerce and nine other departments aimed at promoting high-quality development in the pharmaceutical retail industry, emphasizing the need for an optimized marketing system and fair competition across regions [1] Group 1: Marketing System Optimization - The opinions advocate for deep collaboration between pharmaceutical manufacturers and large national or regional pharmaceutical distribution companies, focusing on market-oriented regulation of drug purchase and sales pricing systems [1] - There is a push to encourage the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2: Competition and Pricing - The document promotes fair competition in the pharmaceutical retail industry across provinces and regions, guiding retail drug prices to remain at reasonable levels [1] - It encourages the opening of data interfaces by pharmaceutical e-commerce platforms to enhance monitoring of online and offline drug retail prices in relation to provincial medical procurement platform prices [1] Group 3: Technology and Data Utilization - The opinions highlight the importance of promoting the application of price comparison indices for designated pharmacies and drug price comparison mini-programs [1]

（文章来源：商务部网站） 商务部等九部门发布关于促进药品零售行业高质量发展的意见。 ...

Core Insights - Shandong Xinhongren Pharmaceutical has been recognized for its comprehensive strength and regional strategic layout by being included in the "2025 China Pharmaceutical Retail Comprehensive Competitiveness Top 100" and the "Top 10 Competitiveness of Central Shandong Urban Agglomeration" [1][3] Group 1: Industry Recognition - The "2025 China Pharmaceutical Retail Comprehensive Competitiveness Top 100" has a sales threshold of 450 million yuan, covering 27 provinces and municipalities, with over six companies from Guangdong and Shandong among the entrants, indicating significant industrial cluster effects [3] - Xinhongren Pharmaceutical ranked 39th in the "2025 China Pharmaceutical Retail Comprehensive Competitiveness Top 100," reflecting its refined operational capabilities and resilience in sustained growth [3] Group 2: Strategic Positioning - The recognition of Xinhongren Pharmaceutical highlights its strategic foresight during the value reconstruction period in pharmaceutical retail, showcasing its ability to adapt to market changes through a collaborative regional network [3] - The company is transitioning from "scale expansion" to "quality development," positioning itself as a new force in the high-quality development of China's pharmaceutical retail industry [3]